Is ondansetron (Zofran) safe for a breastfeeding mother to take?

Ondansetron (Zofran) Safety During Breastfeeding

Ondansetron can be used during breastfeeding with caution, as human data on breast milk transfer are lacking, though the FDA label states it is excreted in rat milk and recommends exercising caution when administering to nursing women. 1

Evidence-Based Safety Assessment

FDA Labeling Position

• The FDA label explicitly states that ondansetron is excreted in the breast milk of rats, but it is unknown whether ondansetron is excreted in human milk 1
• Because many drugs are excreted in human milk, the FDA recommends that caution should be exercised when ondansetron is administered to a nursing woman 1

Professional Guideline Recommendations

• The Association of Anaesthetists (2020) acknowledges that there are no studies on ondansetron transfer into human breast milk, although animal study data exist 2
• The American Academy of Pediatrics (2022) recommends consulting LactMed (the National Library of Medicine's Drugs and Lactation Database) for comprehensive information on maternal medication safety during breastfeeding 2

Recent Pharmacokinetic Modeling Data

• A 2022 physiologically-based pharmacokinetic study of 78 breastfeeding women receiving 4 mg intravenous ondansetron demonstrated that the model-predicted relative infant dose was only 3.0% of the maternal weight-adjusted dose 3
• The calculated daily infant dose was 0.005 mg/kg/day, which is well below the 10% safety threshold typically used to define compatibility with breastfeeding 3
• The study concluded that mothers receiving ondansetron can safely breastfeed based on the low relative infant dose 3

Clinical Decision Algorithm

When Ondansetron May Be Appropriate

• For acute postoperative nausea and vomiting: Ondansetron is commonly used perioperatively and the 2022 pharmacokinetic data support its safety profile 3
• For short-term use: Brief courses (e.g., 1-2 days) carry minimal theoretical risk given the low predicted infant exposure 3
• When alternative antiemetics are ineffective or contraindicated: The benefit of treating severe maternal nausea/vomiting may outweigh the theoretical risk from limited breast milk transfer 2, 1

Preferred Alternative Antiemetics

• Metoclopramide is explicitly compatible with breastfeeding and may actually increase milk supply (used as a galactagogue), making it a preferred first-line option 2
• Prochlorperazine has low oral bioavailability due to high first-pass metabolism and is compatible with breastfeeding 2
• Cyclizine has no reports of levels entering breast milk and is unlikely to produce adverse effects if used short-term 2

Important Clinical Caveats

Lack of Human Data

• The primary limitation is the absence of direct human studies measuring ondansetron concentrations in breast milk, requiring reliance on animal data and pharmacokinetic modeling 2, 1
• The 2022 modeling study provides the strongest available evidence, but it evaluated only a single 4 mg IV dose rather than repeated oral dosing 3

Practical Considerations

• No need to "pump and dump": If ondansetron is used, there is no evidence supporting the practice of expressing and discarding breast milk 2
• Timing considerations: If a mother chooses to minimize theoretical infant exposure, she could take ondansetron immediately after breastfeeding to maximize the interval before the next feeding 2
• Infant monitoring: Watch for any unusual sedation or behavioral changes in the infant, though these have not been reported in available literature 2

Risk-Benefit Context

In real-world clinical practice, the decision should weigh the severity of maternal symptoms against the theoretical (but likely minimal) infant risk. For severe nausea/vomiting that impairs maternal function or hydration, ondansetron use is reasonable given the 3.0% relative infant dose demonstrated in the 2022 study 3. However, for mild-to-moderate symptoms, metoclopramide or prochlorperazine should be considered first-line due to their established compatibility with breastfeeding 2.

The FDA's cautionary language reflects the lack of human data rather than evidence of harm 1. The 2022 pharmacokinetic modeling study provides reassuring quantitative evidence that infant exposure is minimal, though this represents the highest-quality available data rather than definitive proof of safety across all dosing scenarios 3.